BNT162b2 COVID-19 vaccination uptake, safety, effectiveness and waning in children and young people aged 12–17 years in Scotland

BACKGROUND: The two-dose BNT162b2 (Pfizer-BioNTech) vaccine has demonstrated high efficacy against COVID-19 disease in clinical trials of children and young people (CYP). Consequently, we investigated the uptake, safety, effectiveness and waning of the protective effect of the BNT162b2 against sympt...

Descripción completa

Detalles Bibliográficos
Autores principales: Rudan, Igor, Millington, Tristan, Antal, Karen, Grange, Zoe, Fenton, Lynda, Sullivan, Christopher, Buelo, Audrey, Wood, Rachael, Woolford, Lana, Swann, Olivia V., Murray, Josephine L.K., Cullen, Lucy A., Moore, Emily, Haider, Fasih, Almaghrabi, Fatima, McMenamin, Jim, Agrawal, Utkarsh, Shah, Syed Ahmar, Kerr, Steven, Simpson, Colin R., Katikireddi, Srinivasa Vittal, Ritchie, Sir Lewis D., Robertson, Chris, Sheikh, Sir Aziz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514975/
https://www.ncbi.nlm.nih.gov/pubmed/36189425
http://dx.doi.org/10.1016/j.lanepe.2022.100513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514975/
https://www.ncbi.nlm.nih.gov/pubmed/36189425
http://dx.doi.org/10.1016/j.lanepe.2022.100513

Ejemplares similares